Every approach to the same diagnosis, side by side — all categories load from the Layer-1 knowledge file. Two-axis tiers per the CDS Evidence Schema v2 + the 08-22 vetting memo. Every row cites its sources.
⚠ MODEL-DRAFTED SCAFFOLD — every tier is provisional pending Brian's clinical review (Schema v2 rule). Not patient-facing, not a protocol, not marketing. Doses are literature/study doses, not prescriptions. REG tiers: GREEN = lawful today · Y1–Y3 = pathway-gated (see External Vetting Memo §3) · RED = off menu. All three traditional-medicine lanes (Ayurvedic · Chinese herbal · Western/ancient) populated 2026-08-22 from citation-verified literature sweeps (~90 sources; PMID/DOI per row). Standing rule for herbal rows: structure/function language only in any patient-facing use; herb-drug interaction check documented at enrollment; hold blood-moving herbs ≥7 days pre-procedure. Transposition disclosure (mechanism pass, 08-22): where an agent appears under a diagnosis without direct trials there, its tier badge reflects its best-evidenced indication and the use is a labeled mechanistic transposition per Evidence Schema v2 — the Mechanisms tab shows the mapping and rationale per diagnosis.
Therapeutic AtlasInteraction CheckerProcedure Hold TimesMed ArsenalClinical ManualMechanisms & Education
all approaches
Severity = clinical priority for THIS practice's population: HIGH act (avoid / hold / substitute / monitor tightly) · MED counsel + monitor · LOW awareness/spacing. Class-level rules — the row's action governs any member of the med class. PROVISIONAL until Brian's review.
Defaults from ASRA interventional-pain anticoagulation guidelines, 2nd ed (Narouze et al., Reg Anesth Pain Med 2018) + practice rules from the 08-22 herbal sweeps. ⚠ NEVER hold antiplatelets after recent coronary stent (DES <6–12 mo) without cardiology sign-off. Hold/restart decisions coordinate with the prescriber; risk tier is per-procedure AND per-patient. PROVISIONAL — Brian confirms tiers + practice policy rows before deployment.
The practice formulary/arsenal, grouped, with each group's top interaction axes. PROVISIONAL roster drafted from practice records — Brian confirms the formulary.
CLINICAL MANUAL — the teaching layer. Written for a medical audience: selection rationale, pharmacology, study-level evidence with certainty grades, adverse-effect profile, interactions, dosing as studied, and an explicit EVIDENCE GAPS section on every entry — where rigor is missing, the entry says so rather than papering over it. Select a diagnosis, then a discipline, then click any agent to open its monograph. Entries marked CONDENSED carry the atlas summary only; full monographs pending. ⚠ MODEL-DRAFTED from the cited sources — physician editorial review converts this to teaching canon; until then it is a draft manual, not doctrine.
MECHANISMS & EDUCATION — the foundational teaching layer: WHY each diagnosis hurts (the disease mechanisms) and WHY each recommended therapy maps to those mechanisms. Two audiences per diagnosis: STAFF (pathophysiology + mechanism→therapy map, for training Maywell employees on why we recommend what we recommend) and PATIENT (plain-language explanation, suitable as handout source text after physician review). ⚠ MODEL-DRAFTED — physician editorial review required before any patient-facing use; patient text uses honest, non-promissory language by design.